- Home
- INCY vs NIO Comparison
INCY vs NIO Comparison
Compare INCY & NIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- NIO
- Stock Information
- Founded
- INCY 1991
- NIO 2014
- Country
- INCY United States
- NIO China
- Employees
- INCY N/A
- NIO N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- NIO Auto Manufacturing
- Sector
- INCY Health Care
- NIO Consumer Discretionary
- Exchange
- INCY Nasdaq
- NIO Nasdaq
- Market Cap
- INCY 16.1B
- NIO 18.0B
- IPO Year
- INCY 1993
- NIO 2018
- Fundamental
- Price
- INCY $86.85
- NIO $7.68
- Analyst Decision
- INCY Buy
- NIO Buy
- Analyst Count
- INCY 20
- NIO 9
- Target Price
- INCY $80.67
- NIO $6.63
- AVG Volume (30 Days)
- INCY 1.7M
- NIO 92.9M
- Earning Date
- INCY 10-28-2025
- NIO 11-19-2025
- Dividend Yield
- INCY N/A
- NIO N/A
- EPS Growth
- INCY 900.04
- NIO N/A
- EPS
- INCY 4.37
- NIO N/A
- Revenue
- INCY $4,584,996,000.00
- NIO $9,690,436,500.00
- Revenue This Year
- INCY $16.36
- NIO $37.91
- Revenue Next Year
- INCY $10.82
- NIO $39.45
- P/E Ratio
- INCY $19.80
- NIO N/A
- Revenue Growth
- INCY 18.87
- NIO 9.28
- 52 Week Low
- INCY $53.56
- NIO $3.02
- 52 Week High
- INCY $88.66
- NIO $8.02
- Technical
- Relative Strength Index (RSI)
- INCY 59.41
- NIO 63.48
- Support Level
- INCY $81.09
- NIO $6.92
- Resistance Level
- INCY $88.66
- NIO $8.02
- Average True Range (ATR)
- INCY 1.90
- NIO 0.43
- MACD
- INCY 0.02
- NIO 0.02
- Stochastic Oscillator
- INCY 76.09
- NIO 77.92
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.